Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity
Yu Fu, Qing Lin, Zhirong Zhang, et al.
Acta Pharmaceutica Sinica B (2019) Vol. 10, Iss. 3, pp. 414-433
Open Access | Times Cited: 194

Showing 1-25 of 194 citing articles:

Cytokine Storm in COVID-19—Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper
Sonu Bhaskar, Akansha Sinha, Maciej Banach, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 473
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Dongrui Wang, Xianlin Wu, Yingli Sun
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 287
Small molecules targeting the innate immune cGAS‒STING‒TBK1 signaling pathway
Chunyong Ding, Zilan Song, Ancheng Shen, et al.
Acta Pharmaceutica Sinica B (2020) Vol. 10, Iss. 12, pp. 2272-2298
Open Access | Times Cited: 227
Signal pathways of melanoma and targeted therapy
Weinan Guo, Huina Wang, Chunying Li
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 224
Regulatory cells and the effect of cancer immunotherapy
María Iglesias-Escudero, Noelia Arias-González, Eva Martı́nez-Cáceres
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 110
Immunotherapy of Cancer by Targeting Regulatory T cells
Bo-Jin Chen, Jingwen Zhao, Dahong Zhang, et al.
International Immunopharmacology (2022) Vol. 104, pp. 108469-108469
Open Access | Times Cited: 76
Immunotherapies and Combination Strategies for Immuno-Oncology
Cody Barbari, Tyler Fontaine, Priyanka Parajuli, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 14, pp. 5009-5009
Open Access | Times Cited: 100
Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives
Roman P. Labbé, Sandrine Vessillier, Qasim A. Rafiq
Viruses (2021) Vol. 13, Iss. 8, pp. 1528-1528
Open Access | Times Cited: 84
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives
Piera Federico, Angelica Petrillo, Pasqualina Giordano, et al.
Cancers (2020) Vol. 12, Iss. 10, pp. 3025-3025
Open Access | Times Cited: 70
OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors
Martin Gutierrez, Víctor Moreno, Kimberley M. Heinhuis, et al.
Clinical Cancer Research (2020) Vol. 27, Iss. 2, pp. 460-472
Open Access | Times Cited: 70
Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity
Zhangchi Dongye, Jian Li, Yuzhang Wu
British Journal of Cancer (2022) Vol. 127, Iss. 9, pp. 1584-1594
Open Access | Times Cited: 61
Targeting ubiquitin signaling for cancer immunotherapy
Xiaofei Zhou, Shao‐Cong Sun
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 60
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
Andrea De Giglio, Alessandro Di Federico, Giacomo Nuvola, et al.
Current Oncology Reports (2021) Vol. 23, Iss. 11
Open Access | Times Cited: 60
Emerging Trends in Immunotherapy for Cancer
Alok Mishra, Amjad Ali, Shubham Dutta, et al.
Diseases (2022) Vol. 10, Iss. 3, pp. 60-60
Open Access | Times Cited: 46
The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease
Keisuke Sawada, Hak‐Jae Chung, Samir Softic, et al.
Cell Metabolism (2023) Vol. 35, Iss. 11, pp. 1852-1871
Open Access | Times Cited: 34
Cellular and molecular waypoints along the path of T cell exhaustion
Xin Lan, Caitlin C. Zebley, Ben Youngblood
Science Immunology (2023) Vol. 8, Iss. 87
Open Access | Times Cited: 25
OX40L-Armed Oncolytic Virus Boosts T-cell Response and Remodels Tumor Microenvironment for Pancreatic Cancer Treatment
Shiyu Liu, Fan Li, Qiongqiong Ma, et al.
Theranostics (2023) Vol. 13, Iss. 12, pp. 4016-4029
Open Access | Times Cited: 24
Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy
Habib Sadeghirad, Ning Liu, James Monkman, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 23
Converting “cold” to “hot”: epigenetics strategies to improve immune therapy effect by regulating tumor‐associated immune suppressive cells
Yijia Tang, Guangzu Cui, Haicong Liu, et al.
Cancer Communications (2024) Vol. 44, Iss. 6, pp. 601-636
Open Access | Times Cited: 11
OX40/OX40 ligand and its role in precision immune oncology
Bicky Thapa, Shumei Kato, Daisuke Nishizaki, et al.
Cancer and Metastasis Reviews (2024) Vol. 43, Iss. 3, pp. 1001-1013
Open Access | Times Cited: 10
NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy
Leona Rašková Kafková, Joanna Maria Mierzwicka, Prosenjit Chakraborty, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 9
The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers
S Mestiri, Dina Moustafa Abo El-Ella, Queenie Fernandes, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116095-116095
Open Access | Times Cited: 8
Unleashing the Power of immune Checkpoints: A new strategy for enhancing Treg cells depletion to boost antitumor immunity
Guoxin Li, Siqi Li, Yi Jiang, et al.
International Immunopharmacology (2025) Vol. 147, pp. 113952-113952
Open Access | Times Cited: 1
Delivery routes matter: Safety and efficacy of intratumoral immunotherapy
Emily De Lombaerde, Olivier De Wever, Bruno G. De Geest
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2021) Vol. 1875, Iss. 2, pp. 188526-188526
Closed Access | Times Cited: 46
Immune-Checkpoint Inhibitors in B-Cell Lymphoma
Marc Armengol, Juliana C. Santos, Miranda Fernández-Serrano, et al.
Cancers (2021) Vol. 13, Iss. 2, pp. 214-214
Open Access | Times Cited: 41
Page 1 - Next Page

Scroll to top